Metastatic duodenal GIST: role of surgery combined with imatinib mesylate

Table 2 Summary of Imatinib Trials

Trial	Source	Phase	Patients no	Imatinib Dosage	Follow-up	Response Rate
Multicentre Randomized USA Trial	Demetri et al NEJM 2002¹⁵	II	147	400 mg od 600 mg od	34 months median	CR 1% PR – 67% SD – 16% Survival – median NR
EORTC, ISG and AGITG	Van Glabbeke M et al Eur J Cancer^16,17	III	946	400 mg od 400 mg bid	17 months median	CR – 6% PR – 45% SD – 33% Survival – median NR
The Sarcoma Intergroup	Rankin et al Journal of Clinical Oncology 2004¹⁸	III	746	400 mg od 800 mg od	24 months median	CR – 3% PR – 45% SD – 26% Survival – median NR
EORTC	Van Oosterum, Lancet 2001¹⁹	I/II	40	Dose finding 400–1000 mg od	9–13 months	PR – 53% SD – 16%

CR – complete response, NR – Not reached, PR – partial response, SD – stable disease